Brief: Unity Biotechnology reports Q2 results
12/08/2022 12:09
Aug 12 (Reuters) - UNITY Biotechnology Inc UBX.O :
* UNITY BIOTECHNOLOGY, INC. REPORTS SECOND QUARTER
2022 FINANCIAL
RESULTS AND BUSINESS UPDATES
* CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED
$64.5
MILLION AS OF JUNE 30, 2022
* BELIEVES THAT CURRENT CASH, CASH EQUIVALENTS, AND
MARKETABLE
SECURITIES ARE SUFFICIENT TO FUND OPERATIONS THROUGH Q1 OF 2023
* QTRLY LOSS PER SHARE $0.19
* Q2 EARNINGS PER SHARE VIEW $-0.28 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNXVjjyR
Further company coverage: UBX.O
Recent news on Unity Biotechnology
See all newsU.S. STOCKS ON THE MOVE-Eve Holding, Magnite, EHang Holdings
U.S. STOCKS ON THE MOVE-Lamb Weston, Robinhood, Eve Holding
Unity Biotechnology slips as co faces Nasdaq delisting, plans dissolution
Brief: Unity Biotechnology Inc - Board Approves Plan Of Dissolution - SEC Filing
Brief: UNITY Biotechnology Estimates $3.7 Million Expenses For Reduction In Force